Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05771480 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05771480 · ClinicalTrials.gov record · last posted 2026-07-29

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Study acronym: TOURMALINE
StatusActive, Not Recruiting
PhasePhase 3
Started2023-08-16
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.

Amendment record 24 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 24 times since 2023-03-06; most recent amendment 2026-04-20. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-04-03
Status change Recruiting→Active, Not Recruitingv18
2023-09-13
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT05771480
Lead Sponsor AstraZeneca
Conditions Biliary Tract Cancer
Enrollment 142 participants
Start Date 2023-08-16
Primary Completion 2025-10-02 (estimated)
Study Completion 2026-09-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-29